SEC Comment Letter 0000000000-23-011112 to AMARIN CORP PLC\UK (AMRN) (CIK 0000897448) (AMRN)
AMARIN CORP PLC\UK (AMRN) (CIK 0000897448)
Date: Oct. 11, 2023 · CIK: 0000897448 · Accession: 0000000000-23-011112
AI Filing Summary & Sentiment
File numbers found in text: 000-21392
Letter
United States securities and exchange commission logo October 11, 2023 Tom Reilly Executive Vice President and Chief Financial Officer Amarin Corporation plc Iconic Offices, The Greenway 112 – 114 St Stephens Green Block C Ardilaun Court Dublin 2 Re:Amarin Corporation plc Form 10-K for the Fiscal Year Ended December 31, 2022 Filed March 1, 2023 File No. 000-21392 Dear Tom Reilly: We have limited our review of your filing to the financial statements and related disclosures and have the following comments. Please respond to this letter within ten business days by providing the requested information or advise us as soon as possible when you will respond. If you do not believe a comment applies to your facts and circumstances, please tell us why in your response. After reviewing your response to this letter, we may have additional comments. Form 10-K for the Fiscal Year Ended December 31, 2022 Notes to Consolidated Financial Statements Note 2—Significant Accounting Policies Inventory, page F-10 1.Tell us and clarify in future filings the meaning of "normal operating cycle" as used in your accounting policy disclosure and why the criteria is appropriate for classification of inventory as long-term. Discuss the shelf-life associated with your product and explain why you believe you will be able to realize the inventory prior to the expiration of the shelf life.
FirstName LastNameTom Reilly Comapany NameAmarin Corporation plc October 11, 2023 Page 2 FirstName LastName Tom Reilly Amarin Corporation plc October 11, 2023 Page 2 Restructurings, page F-14 2.Please tell us and confirm you will disclose in future filings your accounting policy for recognizing restructuring charges or direct us to existing disclosure. Provide us the GAAP guidance used for your accounting treatment. In closing, we remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Ibolya Ignat at 202-551-3636 or Mary Mast at 202-551-3613 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences
Show Raw Text
United States securities and exchange commission logo
October 11, 2023
Tom Reilly
Executive Vice President and Chief Financial Officer
Amarin Corporation plc
Iconic Offices, The Greenway
112 – 114 St Stephens Green
Block C Ardilaun Court
Dublin 2
Re:Amarin Corporation plc
Form 10-K for the Fiscal Year Ended December 31, 2022
Filed March 1, 2023
File No. 000-21392
Dear Tom Reilly:
We have limited our review of your filing to the financial statements and related
disclosures and have the following comments.
Please respond to this letter within ten business days by providing the requested
information or advise us as soon as possible when you will respond. If you do not believe a
comment applies to your facts and circumstances, please tell us why in your response.
After reviewing your response to this letter, we may have additional comments.
Form 10-K for the Fiscal Year Ended December 31, 2022
Notes to Consolidated Financial Statements
Note 2—Significant Accounting Policies
Inventory, page F-10
1.Tell us and clarify in future filings the meaning of "normal operating cycle" as used in
your accounting policy disclosure and why the criteria is appropriate for classification of
inventory as long-term. Discuss the shelf-life associated with your product and explain
why you believe you will be able to realize the inventory prior to the expiration of
the shelf life.
FirstName LastNameTom Reilly
Comapany NameAmarin Corporation plc
October 11, 2023 Page 2
FirstName LastName
Tom Reilly
Amarin Corporation plc
October 11, 2023
Page 2
Restructurings, page F-14
2.Please tell us and confirm you will disclose in future filings your accounting policy for
recognizing restructuring charges or direct us to existing disclosure. Provide us the GAAP
guidance used for your accounting treatment.
In closing, we remind you that the company and its management are responsible for the
accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or
absence of action by the staff.
Please contact Ibolya Ignat at 202-551-3636 or Mary Mast at 202-551-3613 with any
questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences